IMA Advisory Services’s Acorda Therapeutics ACOR Stock Holding History

IMA Advisory Services’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$13	–	351
2022 Q4	$13	Hold	1	–	–	﹤0.01%	340
2022 Q3	$0	Hold	1	–	–	﹤0.01%	412
2022 Q2	$0	Hold	1	–	–	﹤0.01%	340
2022 Q1	$0	Hold	1	–	–	﹤0.01%	316
2021 Q4	$0	Hold	1	–	–	﹤0.01%	321
2021 Q3	$0	Hold	1	–	–	﹤0.01%	294
2021 Q2	$0	Hold	1	–	–	﹤0.01%	305
2021 Q1	$0	Buy	+1	New	+$123	﹤0.01%	322
2020 Q4	–	Sell	-1	Closed	–	–	329
2020 Q3	$0	Hold	1	–	–	﹤0.01%	309
2020 Q2	$0	Hold	1	–	–	﹤0.01%	260
2020 Q1	$0	Hold	1	–	–	﹤0.01%	296
2019 Q4	$0	Hold	1	–	–	﹤0.01%	288
2019 Q3	$0	Hold	1	–	–	﹤0.01%	291
2019 Q2	$1K	Hold	1	–	–	﹤0.01%	275
2019 Q1	$1K	Hold	1	–	–	﹤0.01%	280
2018 Q4	$2K	Hold	1	–	–	﹤0.01%	302
2018 Q3	$2K	Hold	1	–	–	﹤0.01%	311
2018 Q2	$3K	Buy	+1	New	+$3.06K	﹤0.01%	387

Other funds holding ACOR

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

DKP

Davidson Kempner Partners New York $5.16B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

IMA Advisory Services's ACOR Position: Q1 2023 in Review

IMA Advisory Services sold out of Acorda Therapeutics (ACOR) in Q1 2023, closing a stake of 1 share — an estimated $13 sold.

IMA Advisory Services first reported a position in ACOR in Q2 2018 and held it in 18 quarters. The position peaked at $3K in Q2 2018. 29 funds tracked by Wall St. Rank hold ACOR as of Q1 2023.

IMA Advisory Services reported no remaining Acorda Therapeutics position as of Q1 2023 after selling out during the quarter.
IMA Advisory Services sold 1 Acorda Therapeutics share in Q1 2023, an estimated $13.
IMA Advisory Services first reported a position in Acorda Therapeutics in Q2 2018 and held it in 18 quarters.
IMA Advisory Services's Acorda Therapeutics position peaked at $3K in Q2 2018.
29 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2023.

Based on IMA Advisory Services's 13F filing for Q1 2023, filed 16 May 2023.